Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2020-12-24 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
关于召开2020年第一次临时股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2020 first extraordinary general meeting (临时股东大会) of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items (such as the proposal to add a non-independent director and amend the company charter), registration details, and proxy voting instructions. The document does not contain financial statements or results but serves as a notice and procedural guide for shareholders to participate in the meeting and vote on proposals. It is not a report of voting results, nor is it a proxy solicitation or remuneration report. Given the detailed nature of the meeting notice and instructions, this fits the category of a shareholder meeting announcement rather than the meeting materials or results. According to the filing definitions, this corresponds to AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. Although this is an extraordinary meeting, the category AGM-R is the closest fit for meeting notices and materials related to shareholder meetings. The document length is 4425 characters, which is substantial and contains detailed meeting information, not just a brief announcement or a report publication notice. Therefore, the classification is AGM-R with high confidence.
2020-12-24 Chinese
关于召开2020年第一次临时股东大会的通知的更正公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2020 first extraordinary general meeting (临时股东大会) of Jinling Pharmaceutical Co., Ltd. It includes corrections to a previous notice, detailed meeting arrangements, voting procedures, agenda items, and proxy forms. The content focuses on the notification and procedural details for the shareholders' meeting rather than the meeting results or materials presented at the meeting. There is no indication that this is a report of voting results or a presentation, nor is it a financial report or management discussion. The document is primarily a notice and correction about the meeting itself, which fits the category of announcements related to shareholder meetings. Since it is a notice about convening a shareholders' meeting (临时股东大会), it aligns best with the category AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. Although this is an extraordinary meeting, the AGM-R category is the closest fit for shareholder meeting notices and related materials. The document length is over 5,000 characters and contains substantive content, so it is not a mere report publication announcement or regulatory filing. Therefore, the classification is AGM-R with high confidence.
2020-12-17 Chinese
关于控股子公司南京鼓楼医院集团仪征医院老病房大楼改造项目的进展公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (555 characters) from Jinling Pharmaceutical Co., Ltd. about the progress of a renovation project at a subsidiary hospital. It provides an update on the completion and expected impact of the project but does not contain financial statements, detailed financial data, or regulatory filings such as annual or interim reports. It is not a report itself but an announcement regarding a project progress. The document is not related to board changes, voting results, or legal proceedings. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous announcements that do not fit other specific categories.
2020-12-17 Chinese
关于召开2020年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2020 first extraordinary general meeting of shareholders for Jinling Pharmaceutical Co., Ltd. It details the meeting date, voting procedures (including online voting), agenda items such as the proposal to add a non-independent director and amend the company bylaws, registration details, and proxy voting instructions. There is no financial data, earnings information, or audit content. The document is an announcement informing shareholders about the meeting and how to participate, not the actual meeting minutes or voting results. It fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2020-12-11 Chinese
公司章程修订对照表
Governance Information Classification · 95% confidence The document is a comparison table showing amendments to the articles of association (章程修订对照表) of Jinling Pharmaceutical Co., Ltd. It details changes in the company's business scope and related provisions. This type of document relates to the company's internal governance rules and structure rather than financial performance, audit, or shareholder voting results. It is not a report, announcement of voting results, nor a regulatory filing about financials or management changes. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2020-12-11 Chinese
关于调整公司高级管理人员职务及聘任公司总裁的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding changes in senior management positions, specifically the resignation of the current president and appointment of a new president. It mentions the board meeting date and the approval of these changes. There is no financial data, no mention of financial results, or detailed reports. The content fits the category of announcements about changes in the company's board or senior management.
2020-12-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.